Matches in SemOpenAlex for { <https://semopenalex.org/work/W2418113320> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2418113320 endingPage "20" @default.
- W2418113320 startingPage "114" @default.
- W2418113320 abstract "Although in previous studies no clear demonstration was found of the efficacy of azathioprine, cyclophosphamide and methotrexate as immunoprophylactic agents in cases of multiple sclerosis (MS), over the past five years a number of well-designed clinical trials utilizing immunosuppressive and immunomodulatory agents have shown partial efficacy regarding the drugs involved, but they have not been able to determine in what way these drugs can modify the natural course of this disease. Among the immunosuppressors, mitoxantrone is of particular interest as during the past two years three controlled trials have taken place in Europe and have demonstrated its efficacy both as regards clinical (frequency of symptoms, progression of the disease) and magnetic resonance imaging (MRI) criteria. Due to its potentially severe cardiotoxicity related to total cumulative dose, mitoxantrone is only prescribed for a limited period, and its use is limited to selected patients with a high relapse rate and incomplete remission, or to those who do not respond to beta-interferon treatment. The immunomodulatory agents have less immediate efficacy, but because they are well tolerated they can be used early in the course of the disease and over a prolonged period of time. The beta-interferons (1a or 1b) have been given market approval for use in the treatment of MS: three large, randomized, double-blind studies have demonstrated their capacity to reduce by 30% the frequency of symptoms and the appearance of disabilities associated with relapse and with the progression of the disease. Glatirameracetate or copolymer 1, which is available in France (ATU), has been found to reduce the frequency of relapse by 30%. It constitutes an alternative immunomodulatory treatment for relapsing-remitting patients without major functional disabilities and who suffer from severe side effects with beta-interferon treatment. In the future, the early use of immunomodulatory agents and therapeutic drug combinations may be introduced. Therapeutic trials are currently in progress to determine the viability of this approach." @default.
- W2418113320 created "2016-06-24" @default.
- W2418113320 creator A5059691174 @default.
- W2418113320 creator A5073028141 @default.
- W2418113320 date "2000-03-01" @default.
- W2418113320 modified "2023-09-23" @default.
- W2418113320 title "[Is immunosuppression a future therapeutic strategy for multiple sclerosis?]." @default.
- W2418113320 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10815287" @default.
- W2418113320 hasPublicationYear "2000" @default.
- W2418113320 type Work @default.
- W2418113320 sameAs 2418113320 @default.
- W2418113320 citedByCount "0" @default.
- W2418113320 crossrefType "journal-article" @default.
- W2418113320 hasAuthorship W2418113320A5059691174 @default.
- W2418113320 hasAuthorship W2418113320A5073028141 @default.
- W2418113320 hasConcept C126322002 @default.
- W2418113320 hasConcept C143998085 @default.
- W2418113320 hasConcept C203014093 @default.
- W2418113320 hasConcept C2776694085 @default.
- W2418113320 hasConcept C2776755627 @default.
- W2418113320 hasConcept C2776760755 @default.
- W2418113320 hasConcept C2778233292 @default.
- W2418113320 hasConcept C2779134260 @default.
- W2418113320 hasConcept C2780252810 @default.
- W2418113320 hasConcept C2780640218 @default.
- W2418113320 hasConcept C2780923524 @default.
- W2418113320 hasConcept C2781059491 @default.
- W2418113320 hasConcept C535046627 @default.
- W2418113320 hasConcept C71924100 @default.
- W2418113320 hasConceptScore W2418113320C126322002 @default.
- W2418113320 hasConceptScore W2418113320C143998085 @default.
- W2418113320 hasConceptScore W2418113320C203014093 @default.
- W2418113320 hasConceptScore W2418113320C2776694085 @default.
- W2418113320 hasConceptScore W2418113320C2776755627 @default.
- W2418113320 hasConceptScore W2418113320C2776760755 @default.
- W2418113320 hasConceptScore W2418113320C2778233292 @default.
- W2418113320 hasConceptScore W2418113320C2779134260 @default.
- W2418113320 hasConceptScore W2418113320C2780252810 @default.
- W2418113320 hasConceptScore W2418113320C2780640218 @default.
- W2418113320 hasConceptScore W2418113320C2780923524 @default.
- W2418113320 hasConceptScore W2418113320C2781059491 @default.
- W2418113320 hasConceptScore W2418113320C535046627 @default.
- W2418113320 hasConceptScore W2418113320C71924100 @default.
- W2418113320 hasIssue "2" @default.
- W2418113320 hasLocation W24181133201 @default.
- W2418113320 hasOpenAccess W2418113320 @default.
- W2418113320 hasPrimaryLocation W24181133201 @default.
- W2418113320 hasRelatedWork W1990864893 @default.
- W2418113320 hasRelatedWork W2035620823 @default.
- W2418113320 hasRelatedWork W2065840819 @default.
- W2418113320 hasRelatedWork W2078165472 @default.
- W2418113320 hasRelatedWork W2136139535 @default.
- W2418113320 hasRelatedWork W2171694172 @default.
- W2418113320 hasRelatedWork W2418113320 @default.
- W2418113320 hasRelatedWork W2498643795 @default.
- W2418113320 hasRelatedWork W2755164304 @default.
- W2418113320 hasRelatedWork W62782602 @default.
- W2418113320 hasVolume "48" @default.
- W2418113320 isParatext "false" @default.
- W2418113320 isRetracted "false" @default.
- W2418113320 magId "2418113320" @default.
- W2418113320 workType "article" @default.